Cooper Companies (NASDAQ:COO) Director Lawrence Erik Kurzius Buys 2,000 Shares of Stock

The Cooper Companies, Inc. (NASDAQ:COO) Director Lawrence Erik Kurzius acquired 2,000 shares of the business’s stock in a transaction dated Wednesday, December 17th. The stock was acquired at an average cost of $82.50 per share, with a total value of $165,000.00. Following the purchase, the director directly owned 7,777 shares in the company, valued at $641,602.50. This represents a 34.62% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Lawrence Erik Kurzius also recently made the following trade(s):

• On Monday, September 29th, Lawrence Erik Kurzius bought 2,000 shares of Cooper Companies stock. The stock was acquired at an average price of $68.39 per share, for a total transaction of $136,780.00.

Cooper Companies Trading Up 0.6%

NASDAQ COO traded up $0.51 during trading on Thursday, hitting $82.99. 253,969 shares of the company’s stock traded hands, compared to its average volume of 2,460,825. The stock has a fifty day moving average of $74.16 and a two-hundred day moving average of $71.81. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.89 and a quick ratio of 1.13. The Cooper Companies, Inc. has a 12-month low of $61.78 and a 12-month high of $100.24. The firm has a market cap of $16.26 billion, a P/E ratio of 44.00, a PEG ratio of 2.31 and a beta of 1.05.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings data on Thursday, December 4th. The medical device company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.11 by $0.04. Cooper Companies had a return on equity of 10.02% and a net margin of 9.16%.The firm had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same quarter in the previous year, the business earned $1.04 earnings per share. The company’s quarterly revenue was up 4.6% on a year-over-year basis. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. As a group, sell-side analysts expect that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Cooper Companies declared that its Board of Directors has approved a share buyback program on Wednesday, September 17th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical device company to purchase up to 15.4% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s board of directors believes its shares are undervalued.

Institutional Investors Weigh In On Cooper Companies

Several institutional investors and hedge funds have recently modified their holdings of COO. Vanguard Group Inc. raised its stake in Cooper Companies by 1.8% in the second quarter. Vanguard Group Inc. now owns 24,254,677 shares of the medical device company’s stock worth $1,725,963,000 after buying an additional 421,423 shares in the last quarter. Capital World Investors grew its holdings in shares of Cooper Companies by 25.7% during the 3rd quarter. Capital World Investors now owns 10,551,592 shares of the medical device company’s stock worth $723,417,000 after acquiring an additional 2,159,233 shares during the period. State Street Corp grew its holdings in shares of Cooper Companies by 1.2% during the 2nd quarter. State Street Corp now owns 8,659,741 shares of the medical device company’s stock worth $616,227,000 after acquiring an additional 104,910 shares during the period. Wellington Management Group LLP raised its position in shares of Cooper Companies by 332.9% in the 3rd quarter. Wellington Management Group LLP now owns 6,184,992 shares of the medical device company’s stock worth $424,043,000 after acquiring an additional 4,756,178 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Cooper Companies by 2.5% in the 2nd quarter. Geode Capital Management LLC now owns 5,205,615 shares of the medical device company’s stock valued at $368,893,000 after purchasing an additional 127,907 shares during the period. 24.39% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently weighed in on COO shares. Robert W. Baird raised their target price on shares of Cooper Companies from $85.00 to $98.00 and gave the stock an “outperform” rating in a report on Friday, December 5th. Weiss Ratings reissued a “sell (d+)” rating on shares of Cooper Companies in a research report on Monday. KeyCorp reissued a “sector weight” rating on shares of Cooper Companies in a report on Friday, December 5th. Piper Sandler reaffirmed an “overweight” rating and set a $94.00 price objective (up from $83.00) on shares of Cooper Companies in a research note on Friday, December 5th. Finally, Barclays reissued an “overweight” rating and issued a $91.00 target price on shares of Cooper Companies in a research note on Monday, December 8th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $90.15.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.